BioNTech SEBNTX -0.48%62 Days Payable is 645.77 as of Mar. 2026, which is 141% above its 10-year median of 268.16. GuruFocus rates BNTX with a GF Score™ of 62/100 and a GF Value™ of $89.10 (Fairly Valued). The stock has 5 warning signs investors should review. Among 705 Biotechnology companies, BioNTech SE ranks better than 68.23% on this metric.
The historical rank and industry rank for BioNTech SE's Days Payable or its related term are showing as below:
BNTX'
s Days Payable Range Over the Past 10 Years
Min: 16.93 Med: 268.16 Max: 1284.69
Current: 268.05
During the past 10 years, BioNTech SE's highest Days Payable was 1284.69. The lowest was 16.93. And the median was 268.16.
BNTX's Days Payable is ranked better than 68.23% of 705
companies
in the Biotechnology industry
Industry Median: 113.36
vs BNTX: 268.05
BioNTech SE's Days Payable
increased
from Mar. 2025 (466.64) to Mar. 2026 (645.77).
It may suggest that BioNTech SEdelayed paying its suppliers.
BioNTech SE Days Payable Related Terms
BioNTech SE Days Payable Historical Data
* Premium members only.
The historical data trend for BioNTech SE's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BioNTech SE's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNTech SE Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioNTech SE's Days Payable distribution charts can be found below:
* The bar in red indicates where BioNTech SE's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
BioNTech SE's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNTech SE (BNTX) has a Days Payable of 645.77 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BioNTech SE and its competitors. This is 141% above median its historical median of 268.16. Over the past decade, BioNTech SE's Days Payable has ranged from 16.93 to 1,284.69. According to the industry distribution chart, BioNTech SE ranks #224 out of 705 companies in the Biotechnology industry, placing it in the top 31.8%.
Is BioNTech SE's Days Payable too high?
BioNTech SE's current Days Payable of 645.77 is 141% above median its 10-year median of 268.16. Over the past 10 years, this metric has ranged from a low of 16.93 to a high of 1,284.69. The Biotechnology industry median Days Payable is 113.36. BioNTech SE's value of 645.77 is 469.7% above this industry median. Based on the distribution chart, BioNTech SE ranks #224 out of 705 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioNTech SE has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioNTech SE's Days Payable compare to INCY and INSM?
According to the Biotechnology industry distribution chart, BioNTech SE ranks #224 out of 705 companies for Days Payable. This puts BioNTech SE in the upper half of its industry. The industry median Days Payable is 113.36. BioNTech SE's value of 645.77 is 469.7% above this benchmark. Historically, BioNTech SE's own Days Payable has ranged from 16.93 to 1,284.69 over the past decade. While the company's 10-year median is 268.16 vs. the industry median of 113.36, BioNTech SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.36, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioNTech SE's current Days Payable of 645.77 is 469.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BioNTech SE and its competitors. For the Biotechnology industry, the median Days Payable is 113.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioNTech SE's current Days Payable is 645.77, which is 141% above median its own 10-year median of 268.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNTech SE stock overvalued right now?
Based on GuruFocus' analysis, BioNTech SE (BNTX) is currently considered Fairly Valued. The stock's GF Value™ is $89.10, compared to a current price of $93.81 — trading 5.3% above its estimated fair value. The current Days Payable is 645.77, which is 141% above median its 10-year median of 268.16 and 469.7% above the Biotechnology industry median of 113.36. BioNTech SE's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For BioNTech SE (BNTX), the current Days Payable is 645.77 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNTech SE (BNTX) Overvalued in 2026?
Based on GuruFocus' analysis, BioNTech SE stock appears to be overvalued.
The current stock price of $93.81 is trading 5.3% above its estimated GF Value™ of $89.10.
GuruFocus considers BioNTech SE to be Fairly Valued.
Key valuation signals for BNTX:
Days Payable: 645.77 (141% above median its 10-year median of 268.16)
GF Value™: $89.10 vs. price of $93.81 (5.3% above fair value)
Industry Position: 469.7% above the Biotechnology median (#224 of 705)
No single metric tells the full story. See the BNTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
62GF Score
Get the complete analysis for BNTX
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BNTX has been successfully added to your 
